M
Mathieu Lupien
Researcher at Princess Margaret Cancer Centre
Publications - 166
Citations - 13441
Mathieu Lupien is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Chromatin & Epigenetics. The author has an hindex of 52, co-authored 155 publications receiving 10903 citations. Previous affiliations of Mathieu Lupien include Ontario Institute for Cancer Research & Harvard University.
Papers
More filters
Journal ArticleDOI
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Mathieu Lupien,Jérôme Eeckhoute,Clifford A. Meyer,Qianben Wang,Yong Zhang,Wei Li,Jason S. Carroll,X. Shirley Liu,Myles Brown +8 more
TL;DR: It is demonstrated that genome-wide positional analyses suggest that methylation of histone H3 lysine 4 is part of the epigenetic signature that defines lineage-specific FoxA1 recruitment sites in chromatin.
Journal ArticleDOI
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
Qianben Wang,Wei Li,Yong Zhang,Xin Yuan,Kexin Xu,Jindan Yu,Zhong Chen,Rameen Beroukhim,Rameen Beroukhim,Hongyun Wang,Mathieu Lupien,Tao Wu,Meredith M. Regan,Clifford A. Meyer,Jason S. Carroll,Arjun K. Manrai,Olli A. Jänne,Steven P. Balk,Rohit Mehra,Bo Han,Arul M. Chinnaiyan,Mark A. Rubin,Lawrence D. True,Michelangelo Fiorentino,Christopher Fiore,Massimo Loda,Philip W. Kantoff,X. Shirley Liu,Myles Brown +28 more
TL;DR: The role of AR in androgen-independent cancer cells is not to direct the androgen -dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgens-independent growth.
Journal ArticleDOI
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Stephen C. Mack,Hendrik Witt,Rosario M. Piro,L. Gu,Scott Zuyderduyn,Adrian M. Stütz,Xin Wang,Marco Gallo,Livia Garzia,Kory Zayne,Xiaoyang Zhang,Vijay Ramaswamy,Natalie Jäger,David T.W. Jones,Martin Sill,T. J. Pugh,Marina Ryzhova,Khalida Wani,David Shih,Renee Head,Marc Remke,Swneke D. Bailey,Thomas Zichner,Claudia C. Faria,Mark Barszczyk,Sebastian Stark,Huriye Seker-Cin,Sonja Hutter,Pascal Johann,Sebastian Bender,Volker Hovestadt,Theophilos Tzaridis,Adrian M. Dubuc,Paul A. Northcott,John Peacock,Kelsey C. Bertrand,Sameer Agnihotri,Florence M.G. Cavalli,Ian D. Clarke,K. Nethery-Brokx,Caretha L. Creasy,Sharad K. Verma,Jan Koster,Xiaochong Wu,Yuan Yao,Till Milde,Patrick Sin-Chan,Jennifer Zuccaro,Loretta Lau,Sergio L. Pereira,Pedro Castelo-Branco,Martin Hirst,Marco A. Marra,Stephen S. Roberts,Daniel W. Fults,Luca Massimi,Yoon Jae Cho,T. Van Meter,Wiesława Grajkowska,Boleslaw Lach,Andreas E. Kulozik,A. von Deimling,Olaf Witt,Stephen W. Scherer,Xing Fan,Karin M. Muraszko,Marcel Kool,Scott L. Pomeroy,Nalin Gupta,Joanna J. Phillips,Annie Huang,Uri Tabori,Cynthia Hawkins,David Malkin,Paul Kongkham,William A. Weiss,Nada Jabado,James T. Rutka,Eric Bouffet,Jan O. Korbel,Mathieu Lupien,Kenneth Aldape,Gary D. Bader,Roland Eils,Peter Lichter,Peter B. Dirks,Stefan M. Pfister,Andrey Korshunov,Michael D. Taylor +88 more
TL;DR: It is concluded that epigenetic modifiers are the first rational therapeutic candidates for this deadly malignancy, which is epigenetically deregulated but genetically bland.
Journal ArticleDOI
Nucleosome dynamics define transcriptional enhancers.
Housheng Hansen He,Clifford A. Meyer,Hyunjin Shin,Shannon T. Bailey,Gang Wei,Qianben Wang,Qianben Wang,Yong Zhang,Yong Zhang,Kexin Xu,Min Ni,Mathieu Lupien,Mathieu Lupien,Piotr A. Mieczkowski,Jason D. Lieb,Keji Zhao,Myles Brown,X. Shirley Liu +17 more
TL;DR: In this article, the authors performed genome-wide mapping of epigenetically marked nucleosomes to determine their position both near transcription start sites and at distal regulatory elements, including enhancers.
Journal ArticleDOI
Genomic hallmarks of localized, non-indolent prostate cancer
Michael Fraser,Veronica Y. Sabelnykova,Takafumi N. Yamaguchi,Lawrence E. Heisler,Julie Livingstone,Vincent Huang,Yu Jia Shiah,Fouad Yousif,Xihui Lin,Andre P. Masella,Natalie S. Fox,Natalie S. Fox,Michael Xie,Stephenie D. Prokopec,Alejandro Berlin,Emilie Lalonde,Emilie Lalonde,Musaddeque Ahmed,Dominique Trudel,Xuemei Luo,Timothy Beck,Alice Meng,Junyan Zhang,Alister D'Costa,Robert E. Denroche,Haiying Kong,Shadrielle Melijah G. Espiritu,Melvin L.K. Chua,Ada Wong,Taryne Chong,Michelle Sam,Jeremy Johns,Lee Timms,Nicholas Buchner,Michèle Orain,Valérie Picard,Hélène Hovington,Alexander Murison,Ken Kron,Nicholas J. Harding,Christine P'ng,Kathleen E. Houlahan,Kenneth C. Chu,Bryan Lo,Francis Nguyen,Constance H. Li,Constance H. Li,Ren X. Sun,Ren X. Sun,Richard de Borja,Christopher I Cooper,Julia F. Hopkins,Shaylan K. Govind,Clement Fung,Daryl Waggott,Jeffrey Green,Syed Haider,Michelle Chan-Seng-Yue,Esther Jung,Zhiyuan Wang,Alain Bergeron,Alan Dal Pra,Louis Lacombe,Colin Collins,Colin Collins,Cenk Sahinalp,Mathieu Lupien,Mathieu Lupien,Neil E. Fleshner,Housheng Hansen He,Housheng Hansen He,Yves Fradet,Bernard Têtu,Theodorus van der Kwast,John Douglas Mcpherson,John Douglas Mcpherson,Robert G. Bristow,Robert G. Bristow,Paul C. Boutros,Paul C. Boutros +79 more
TL;DR: It is suggested that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates and numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberration outperformed well-described prognostic biomarkers.